These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37752381)

  • 21. The effects of maternal iron deficiency on infant fibroblast growth factor-23 and mineral metabolism.
    Braithwaite VS; Prentice A; Darboe MK; Prentice AM; Moore SE
    Bone; 2016 Feb; 83():1-8. PubMed ID: 26453792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast growth factor 23 is pumping iron: C-terminal-fibroblast growth factor 23 cleaved peptide and its function in iron metabolism.
    Courbon G; David V
    Curr Opin Nephrol Hypertens; 2024 Jul; 33(4):368-374. PubMed ID: 38661434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.
    Hanudel MR; Eisenga MF; Rappaport M; Chua K; Qiao B; Jung G; Gabayan V; Gales B; Ramos G; de Jong MA; van Zanden JJ; de Borst MH; Bakker SJL; Nemeth E; Salusky IB; Gaillard CAJM; Ganz T
    Nephrol Dial Transplant; 2019 Dec; 34(12):2057-2065. PubMed ID: 30007314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
    Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y; Olauson H; Vavilis G; Hammar U; Herthelius M; Axelsson J; Bárány P
    Pediatr Nephrol; 2018 Jan; 33(1):147-157. PubMed ID: 28795324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of fibroblast growth factor 23 with urate metabolism in patients with chronic kidney disease.
    Sakoh T; Nakayama M; Tsuchihashi T; Yoshitomi R; Tanaka S; Katafuchi E; Fukui A; Shikuwa Y; Anzai N; Kitazono T; Tsuruya K
    Metabolism; 2016 Oct; 65(10):1498-507. PubMed ID: 27621185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
    Womack R; Berru F; Panwar B; Gutiérrez OM
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating Fibroblast Growth Factor-23 Levels are Associated with an Increased Risk of Anemia Development in Patients with Nondialysis Chronic Kidney Disease.
    Nam KH; Kim H; An SY; Lee M; Cha MU; Park JT; Yoo TH; Lee KB; Kim YH; Sung SA; Lee J; Kang SW; Choi KH; Ahn C; Han SH
    Sci Rep; 2018 May; 8(1):7294. PubMed ID: 29740119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF23 in Chronic Kidney Disease: Bridging the Heart and Anemia.
    Figurek A; Rroji M; Spasovski G
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
    Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
    Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Cai X; Lee J; Scialla JJ; Bansal N; Sondheimer JH; Chen J; Hamm LL; Ricardo AC; Navaneethan SD; Deo R; Rahman M; Feldman HI; Go AS; Isakova T; Wolf M;
    JAMA Cardiol; 2016 Aug; 1(5):548-56. PubMed ID: 27434583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Versus Intravenous Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients on Maintenance Hemodialysis-Effect on Fibroblast Growth Factor-23 Metabolism.
    Fukao W; Hasuike Y; Yamakawa T; Toyoda K; Aichi M; Masachika S; Kantou M; Takahishi SI; Iwasaki T; Yahiro M; Nanami M; Nagasawa Y; Kuragano T; Nakanishi T
    J Ren Nutr; 2018 Jul; 28(4):270-277. PubMed ID: 29703633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between serum phosphate levels and anemia in non-dialysis patients with chronic kidney disease: a retrospective cross-sectional study from the Fuji City CKD Network.
    Kato K; Nakashima A; Ohkido I; Kasai K; Yokoo T
    BMC Nephrol; 2023 Aug; 24(1):244. PubMed ID: 37605118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.
    Pavik I; Jaeger P; Ebner L; Wagner CA; Petzold K; Spichtig D; Poster D; Wüthrich RP; Russmann S; Serra AL
    Nephrol Dial Transplant; 2013 Feb; 28(2):352-9. PubMed ID: 23129826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disordered FGF23 and mineral metabolism in children with CKD.
    Portale AA; Wolf M; Jüppner H; Messinger S; Kumar J; Wesseling-Perry K; Schwartz GJ; Furth SL; Warady BA; Salusky IB
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):344-53. PubMed ID: 24311704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strength of Fibroblast Growth Factor 23 as a Cardiovascular Risk Predictor in Chronic Kidney Disease Weaken by ProBNP Adjustment.
    Emrich IE; Brandenburg V; Sellier AB; Schauerte J; Wiedenroth J; Untersteller K; Lennartz CS; Seiler-Mussler S; Wagenpfeil S; Fliser D; Heine GH
    Am J Nephrol; 2019; 49(3):203-211. PubMed ID: 30808827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease.
    Xu H; Hashem A; Witasp A; Mencke R; Goldsmith D; Barany P; Bruchfeld A; Wernerson A; Carrero JJ; Olauson H
    Nephrol Dial Transplant; 2019 Dec; 34(12):2051-2057. PubMed ID: 30312430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
    Biruete A; Metzger CE; Chen NX; Swallow EA; Vrabec C; Clinkenbeard EL; Stacy AJ; Srinivasan S; O'Neill K; Avin KG; Allen MR; Moe SM
    Nephrol Dial Transplant; 2022 Sep; 37(10):1857-1867. PubMed ID: 35482713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.